BeBetter Medicine
1 known investors
Guangzhou-based developer of small molecule drugs for lymphoma, lung cancer, and ovarian cancer, including BEBT-908, a dual-target drug for recurrent or refractory lymphoma.
Investors · 1
Frequently asked questions
- What does BeBetter Medicine do?
- Guangzhou-based developer of small molecule drugs for lymphoma, lung cancer, and ovarian cancer, including BEBT-908, a dual-target drug for recurrent or refractory lymphoma.
- Who are BeBetter Medicine's investors?
- BeBetter Medicine's investors include Ming capital.